Uric Acid, Serum
Uric acid is the final product of purine metabolism in the human organism. Uric acid measurements are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation, or other wasting conditions, and in patients receiving cytotoxic drugs. An increase in serum uric acid concentration occurs with urate overproduction states such as increased nucleoprotein synthesis or catabolism (blood dyscrasias, therapy of leukemia, etc.) or decreased renal uric acid excretion states (e.g., thiazide diuretic therapy or renal failure). In some disorders, such as gout, increased uric acid levels can lead to crystal formation (sodium urate crystals) which can be found microscopically in synovial fluid and tissues and are diagnostic of gout.
Patients with gout always have increased uric acid (hyperuricemia). However, not all patients with elevated serum uric acid develop gout. In addition, increased levels are also found in cellular destruction such as leukemia, myeloproliferative disorders, lymphomas, and other cancerous proliferative diseases. Therefore, uric acid levels must be monitored in these disorders. In these kinds of disorders, lactic acid levels are also increased and should be monitored. In addition, increased uric acid level is also associated with the risk of coronary artery disease.
- Aid in diagnosis and treatment of renal disorders and renal failure
- Diagnosis of gout
- As an aid in monitoring of patients with leukemia and lymphoma and other myeloproliferative disorders
- As an aid in diagnosis of liver diseases (decreased synthesis)
- For monitoring cytotoxic therapy treatment
- Aids monitoring of patients with psoriasis
Increased in:
- Renal failure
- Gout
- Leukemia
- Lymphoma
- Polycythemia Vera
- Myeloma
- Psoriasis
- Glycogen Storage Disease type I
- Lesch-Nyhan syndrome
- Chemotherapy
- Therapeutic Radiation
- Lead Nephropathy, chronic
- Pre-eclampsia and Eclampsia
- Hypertension
- Hyperuricemia
- Dyslipidemia
- Increased with use of some drugs: antimetabolite and chemotherapeutic agents, diuretics, ethanol, nicotinic acid, theophylline
- Down syndrome
- Polycystic kidney disease
- Purine-rich diet (liver, kidney, sweetbread)
Decreased in:
- Syndrome of Inappropriate ADH
- Xanthine Oxidase Deficiency (xanthinuria)
- Low-Purine Diet
- Fanconi Syndrome
- Certain Neoplastic Diseases
- Liver Disease
- Decreased with use of some drugs: allopurinol
- Wilson's disease
- Adenosine deaminase deficiency
- Purine and nucleoside phosphorylase deficiency
Serum (mg/dL / umol/L)
| Group | mg/dL | umol/L |
| Child <12 yr | 2.0–5.5 | 119–327 |
| Adult M | 4.4–7.6 | 262–452 |
| Adult F | 2.3–6.6 | 137–393 |
| 60–90 yr M | 4.2–8.0 | 250–476 |
| 60–90 yr F | 3.5–7.3 | 208–434 |
| >90 yr M | 3.5–8.3 | 208–494 |
| >90 yr F | 2.2–7.7 | 131–458 |
| CSF | 85–932 | 5–55 |
Urine, Random
| Group | mg/dL | umol/L |
| Male <40 yr | 9–63 | 0.53–3.7 |
| Male >40 yr | 6–114 | 0.35–6.7 |
| Female <40 yr | 6–71 | 0.35–4.2 |
| Female >40 yr | 4–93 | 0.24–5.5 |
| Urine, 24 hr | 250–750 | 1.48–4.43 |
Colorimetry, High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS).
Serum (SST) or plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Curr Opin Rheumatol. 2002;14:281. [PMID: 11981327]
- Semin Nephrol. 2005;25:43. [PMID: 15660334]
- BJOG. 2006;113:369. [PMID: 16553648 ]
- Curr Opin Nephrol Hypertens. 2009 Nov;18(6):526-30. [PMID: 19654543]
- Curr Opin Rheumatol. 2006;18:199. [PMID: 16462529]
- Jacobs DS, DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001)
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757